Kadmon — Technical Presentation (May 2020)
23 slides from Kadmon's technical presentation, May 21, 2020
Slide 1: ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD
8 Kadmon ROCkKstar: Pivotal Trial of Belumosudil (KDO25) in CGVHD KD025-213 Primary Analysis Topline Results May 21°¢, 2020
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains “forward-looking” statements that are based on the beliefs and assumptions of, and on information currently available to, management of Kadmon Holdings, Inc. (the “Company’). All statements other than statements of historical fact contained in thi
Slide 3: CEO Opening Remarks
CEO Opening Remarks Harlan W. Waksal, M.D., President and CEO
Slide 4: ROCKstar (KD025-213): Primary Analysis Outcomes
ROCKstar (KD025-213): Primary Analysis Outcomes e Belumosudil (KD025) met the primary endpoint of Overall Response Rate (ORR) in the pivotal trial in cGVHD patients who have received 2 or more prior lines of systemic therapy: — 73% ORR with KD025 200 mg QD (95% Cl: 60%, 83%) — 74% ORR with KD025 200
Slide 5: ROCKstar Primary Analysis Results
ROCKstar Primary Analysis Results KD025-213: Pivotal Clinical Trial of Belumosudil (KD025) in c6VHD Sanjay Aggarwal, M.D., Senior Vice President, Clinical Development
Slide 6: ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD
ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD ROCKstar (KD025-213): A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Primary Endpoint: + ORR, per 2014 NIH criteria KD025
Slide 7: ROCKstar: Statistical Analysis Plan
ROCkKstar: Statistical Analysis Plan Primary Endpoint: ORR Statistical significance is achieved if the lower bound of the 95% Cl of ORR exceeds 30% a Primary endpoint met at interim analysis pet 2 months after completion of enrollment y Data presented at TCT, February 2020 macy 6 months after comple
Slide 8: ROCKstar: Advanced Patient Population
ROCkKstar: Advanced Patient Population Demographics and Baseline Characteristics Demographics KD025 QD (n=66) KD025 BID (n=66) Median age [years (range)] 53 (21-77) 57 (21-77) Male (%) 64 50 Median prior lines of therapy 2 4 Median time from cGVHD diagnosis to enrollment (months) 25 30 NIH Severe cG
Slide 9: ROCKstar Met Primary Endpoint
ROCKstar Met Primary Endpoint 100% 95% 73% 74% e Belumosudil (KD025) achieved 90% (95% Cl: 60%, 83%)" (95% Cl: 62%, 84%)? clinically and statistically significant ene ORRs in both arms fo 75% ; 70% e Complete responses have observed in 65% all affected organ systems 60% 55% e Four patients have achi
Slide 10: ROCKstar Met Primary Endpoint
ROCKstar Met Primary Endpoint 100% 95% 73% 74% e Belumosudil (KD025) achieved 90% (95% Cl: 60%, 83%)" (95% Cl: 62%, 84%)? clinically and statistically significant 85% ORRs in both arms 80% 75% 70% 65% 60% 55% 50% 45% 40% 35% 30% me 25% 20% 15% 10% 5% 0% e Complete responses have observed in all affe
Slide 11: ROCKstar: Responses Observed Across All Key Subgroups
ROCkKstar: Responses Observed Across All Key Subgroups mITT —_o— 200 mg QD (n=66, 73%) —o— 200 mg BID (n=66, 74%) Prior Lines of Therapy Oe = 4 (n=65, 71%) —e— <4 (1-67, 76%) NIH Severity Best Response to Prior Line on co Severe (n=89, 72%) a Refractory (n=79, 73%) —_——e——. Non-Severe (n=43, 77%) ——
Slide 12: ROCKstar: Durability of Response
ROCkKstar: Durability of Response e Durable responses achieved with belumosudil (KD025): — 49% of responders have maintained responses for = 20 weeks — Median duration of response (DOR) has not yet been reached — ROCKstar durability data continue to mature e In earlier Phase 2a trial of belumosudil
Slide 13: ROCKstar: Safety and Tolerability
ROCkKstar: Safety and Tolerability KD025@D KD025 BID e AEs were overall consistent with those expected in Commons epee dee m8) (n=66) (n=66) cGVHD patients receiving corticosteroids and other immunosuppressants All Grade, in 220% ¢ No CMV infection or reactivation observed Fatigue 26 (39) 16 (24) e
Slide 14: ROCKstar Pivotal Trial: Primary Analysis Summary
ROCkKstar Pivotal Trial: Primary Analysis Summary e Belumosudil (KD025) met the primary endpoint in pivotal trial in cGVHD: — 73% and 74% ORR with belumosudil 200 mg QD and 200 mg BID, respectively ¢ 49% of responders have maintained responses for 220 weeks — Median DOR has not yet been reached; dur
Slide 15: Commercial Overview
Commercial Overview Haya Taitel, RPh, Senior Vice President, Chief Commercial Officer
Slide 16: Significant cGVHD Market with Unmet Medical Needs
Significant CGVHD Market with Unmet Medical Needs 7,000 — 10,000 cGVHD patients require additional systemic therapy beyond steroids e Significant cGVHD market — 5,000 new cGVHD patients/year’ — 5-year overall survival of 55%? e Unmet therapeutic needs — Steroids are standard of care in frontline tre
Slide 17: Patients are Concentrated at Academic Transplant Centers
Patients are Concentrated at Academic Transplant Centers 80% of cGVHD Patients are Treated at 70 Transplant Centers a : | A Efficient Field a . - Dees ¢ . Footprint <15 total field associates to address cGVHD market Top Allo-HCT center by volume @ KD025-213 trial site Dark green indicates higher all
Slide 18: Commercial Infrastructure in Place
Commercial Infrastructure in Place Supply Chain i Legal / Compliance Regulatory Affairs Quality Assurance Kadmon Pharmaceuticals: Commercial operation based in Warrendale, PA
Slide 19: Components in Place to Launch and Commercialize KD025
Components in Place to Launch and Commercialize KD025 Existing Commercial Infrastructure Experienced Team Strategic Launch Plan
Slide 20: Belumosudil in cGVHD: Path Forward
Belumosudil in cGVHD: Path Forward Harlan W. Waksal, M.D., President and CEO $ Kadmon:
Slide 21: Belumosudil: A Novel cGVHD Treatment
Belumosudil: A Novel cGVHD Treatment Observed in KD025-208 and ROCKstar (KD025-213) Clinical Trials VY Efficacy — high response rates in advanced cGVHD patients Os Improvement in QOL * KD025-208 follow-up data 8 kadmon
Slide 22: Belumosudil (KD025) in cGVHD: Path Forward
Belumosudil (KDO25) in cGVHD: Path Forward * NDA submission for belumosudil (KD025) in cGVHD planned Q4 2020 — Pre-NDA meeting with FDA took place in March 2020 — Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program — FDA Breakthrough Therapy Designation and Orphan Drug
Slide 23: Q&A
Q&A